公开(公告)号：EP3280795A1

公开(公告)日：2018-02-14

申请号：EP16718786.3

申请日：2016-04-07

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania ,  Byrd, John ,  Dubovsky, Jason ,  Johnson, Amy ,  June, Carl, H. ,  Muthusamy, Natarajan ,  Porter, David L. ,  Wasik, Mariusz

发明人： BYRD, John ,  DUBOVSKY, Jason ,  JOHNSON, Amy ,  JUNE, Carl, H. ,  MUTHUSAMY, Natarajan ,  PORTER, David, L. ,  WASIK, Mariusz ,  ANGST, Daniela ,  FRAIETTA, Joseph, A. ,  GESSIER, Francois ,  GILL, Saar ,  MAUS, Marcela ,  RUELLA, Marco ,  VULPETTI, Anna

IPC分类号： C12N5/0783 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0636 ,  A61K2300/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.